**Genetically Engineered Mouse Models for Human Lung Cancer**

[89] Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated

[90] Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial.

[91] de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 2011, Mar 10;29(8):1067-74.

[92] Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, et al. Vandetanib versus place‐ bo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-

[93] Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multi‐ center, phase II trial of sunitinib in previously treated, advanced non-small-cell lung

[94] Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated ad‐

[95] Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from

[96] Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-

[97] Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, et al. Inter‐ national, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell

[98] Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angio‐ kinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung

[99] Wakelee HA, Gettinger SN, Engelman JA. A phase ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer

vanced non-small cell lung cancer. Br J Cancer 2009, Nov 3;101(9):1543-8.

a phase II study. J Clin Oncol 2009, Aug 10;27(23):3836-41.

lung cancer: MONET1. J Clin Oncol 2012, Aug 10;30(23):2829-36.

cell lung cancer. Ann Oncol 2011, Sep;22(9):2057-67.

cancer. Ann Oncol 2011, Jun;22(6):1374-81.

(NSCLC); J Clin Oncol. 2010;28(15s): abstract 3017.

blind phase III trial (ZEPHYR). J Clin Oncol 2012, Apr 1;30(10):1114-21.

non small-cell lung cancer. J Clin Oncol 2007, Sep 20;25(27):4270-7.

Lancet Oncol 2010, Jul;11(7):619-26.

28 Oncogenesis, Inflammatory and Parasitic Tropical Diseases of the Lung

cancer. J Clin Oncol 2008, Feb 1;26(4):650-6.

Kazushi Inoue, Elizabeth Fry, Dejan Maglic and Sinan Zhu

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53721
